Oric (ORIC) CFO Dominic Piscitelli Sells Shares, Exercises Options

What Happened

• Dominic Piscitelli, Chief Financial Officer of Oric Pharmaceuticals (ORIC), reported option activity and open‑market sales on 2026-09-24. He exercised options to acquire 600 shares at $4.36 per share (cost $2,616). On the same date he sold 600 shares in the open market (100 shares at $13.50 and 500 shares at $13.51) for total proceeds of $8,103.
• The filing also reports a separate derivative disposition of 600 shares at $0.00 (reported as a derivative conversion/disposition) with no cash proceeds; the Form 4 does not provide additional mechanics for that line.

Key Details

• Transaction date: 2026-09-24.
• Exercise: 600 shares acquired at $4.36 each (total $2,616).
• Sales: 100 shares @ $13.50 ($1,350) and 500 shares @ $13.51 ($6,753) — total sale proceeds reported $8,103.
• Derivative disposition: 600 shares @ $0.00 reported as disposed (no proceeds).
• Footnote: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted May 26, 2026.
• Shares owned after the transactions: not disclosed in the provided data.
• Filing timeliness: Form 4 was filed 2026-09-25 for 9/24 transactions (filed the next business day).

Context

• This was an option exercise combined with open‑market sales. Exercising options is a non‑market‑sentiment action (acquiring shares by paying the strike); the simultaneous open‑market sales were executed under a pre‑arranged 10b5‑1 plan (routine selling program).
• The reported derivative disposition at $0.00 may reflect conversion, surrender, or other non‑cash mechanics, but the Form 4 here does not detail the exact mechanics — consult the official filing for full line‑item context.